FDA supplemental approval: Morphine Sulfate (REMS)

AI Summary

The FDA approved a Risk Evaluation and Mitigation Strategy (REMS) supplement for Teva's morphine sulfate extended-release capsules (30 mg, 60 mg, 70 mg, and 100 mg formulations) on 18 June 2026. This is a regulatory action establishing risk management requirements; the record does not contain clinical trial results or efficacy data.

Plain-language summary

FDA supplemental approval of a Risk Evaluation and Mitigation Strategy (REMS) for morphine sulfate extended-release capsules; this is a regulatory action, not a clinical evidence trial.

Reported figures

Quoted from the source exactly as published.

Clinical bottom line

This record reflects FDA regulatory oversight of risk mitigation for opioid products. Healthcare professionals should ensure patient enrollment and monitoring comply with the approved REMS programme, which includes requirements for provider certification, patient agreements, and periodic safety monitoring.

Caveats

• This record contains no clinical trial data, efficacy outcomes, or comparative safety results.
• Details of REMS requirements (e.g., prescriber training, patient monitoring protocols) are not included in this record.
• No information on why the REMS supplement was necessary or what changes it made to the existing REMS.

Evidence assessment

Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.

Follow from this

Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.